MarketBeat
05 Oct 2026, 03:02 UTC · 2h ago
Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study
Impact · against what's priced in
Immix Biopharma (IMMX) is poised for a valuation rerating based on high complete-response rates (89% to 98%) and strong organ-specific efficacy for NXC-201. The clarity on a 2027 BLA timeline, coupled with a cash runway extending into Q1 2029, significantly derisks the transition from clinical to commercial phases.
- IMMX+0.90
No priced-in read yet
- In context
The 89% complete response rate and potential for 98% efficacy in AL amyloidosis, combined with a 100% cardiac response rate, provide a strong clinical foundation for the planned 2027 BLA. A capital raise extending the runway to Q1 2029 removes immediate financing risk for the upcoming frontline trial.
